Literature DB >> 24314205

Summer Meeting 2013: growth and physiology of bifidobacteria.

L De Vuyst1, F Moens, M Selak, A Rivière, F Leroy.   

Abstract

Bifidobacteria are a minor fraction of the human colon microbiota with interesting properties for carbohydrate degradation. Monosaccharides such as glucose and fructose are degraded through the bifid shunt, a dedicated pathway involving phosphoketolase activity. Its stoechiometry learns that three moles of acetate and two moles of lactate are produced per two moles of glucose or fructose that are degraded. However, deviations from this 3 : 2 ratio occur, depending on the rate of substrate consumption. Slower growth rates favour the production of acetate and pyruvate catabolites (such as formate) at the cost of lactate. Interestingly, bifidobacteria are capable to degrade inulin-type fructans (ITF) (oligofructose and inulin) and arabinoxylan-oligosaccharides (AXOS). Beta-fructofuranosidase activity enables bifidobacteria to degrade ITF. However, this property is strain-dependent. Some strains consume both fructose and oligofructose, with different preferences and degradation rates. Small oligosaccharides (degree of polymerization or DP of 2-7) are taken up, in a sequential order, indicating intracellular degradation and as such giving these bacteria a competitive advantage towards other inulin-type fructan degraders such as lactobacilli, bacteroides and roseburias. Other strains consume long fractions of oligofructose and inulin. Exceptionally, oligosaccharides with a DP of up to 20 (long-chain inulin) are consumed by specific strains. Also, the degradation of AXOS by α-arabinofuranosidase and β-xylosidase is strain-dependent. Particular strains consume the arabinose substituents, whether or not together with a consumption of the xylose backbones of AXOS, either up to xylotetraose or higher and either extra- or intracellularly. The production of high amounts of acetate that accompanies inulin-type fructan degradation by bifidobacteria cross-feeds other colon bacteria involved in the production of butyrate. However, bifidobacterial strain-dependent differences in prebiotic degradation indicate the existence of niche-specific adaptations and hence mechanisms to avoid competition among each other and to favour coexistence with other colon bacteria.
© 2013 The Society for Applied Microbiology.

Entities:  

Keywords:  arabinoxylan-oligosaccharides; bifidobacteria; cross-feeding; inulin-type fructans

Mesh:

Substances:

Year:  2013        PMID: 24314205     DOI: 10.1111/jam.12415

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  27 in total

1.  Mutual Cross-Feeding Interactions between Bifidobacterium longum subsp. longum NCC2705 and Eubacterium rectale ATCC 33656 Explain the Bifidogenic and Butyrogenic Effects of Arabinoxylan Oligosaccharides.

Authors:  Audrey Rivière; Mérilie Gagnon; Stefan Weckx; Denis Roy; Luc De Vuyst
Journal:  Appl Environ Microbiol       Date:  2015-08-28       Impact factor: 4.792

2.  In vitro fermentation of copra meal hydrolysate by human fecal microbiota.

Authors:  Phatcharin Prayoonthien; Robert A Rastall; Sofia Kolida; Sunee Nitisinprasert; Suttipun Keawsompong
Journal:  3 Biotech       Date:  2019-02-19       Impact factor: 2.406

3.  A Human Gut Commensal Ferments Cranberry Carbohydrates To Produce Formate.

Authors:  Ezgi Özcan; Jiadong Sun; David C Rowley; David A Sela
Journal:  Appl Environ Microbiol       Date:  2017-08-17       Impact factor: 4.792

4.  Complementary Mechanisms for Degradation of Inulin-Type Fructans and Arabinoxylan Oligosaccharides among Bifidobacterial Strains Suggest Bacterial Cooperation.

Authors:  Audrey Rivière; Marija Selak; Annelies Geirnaert; Pieter Van den Abbeele; Luc De Vuyst
Journal:  Appl Environ Microbiol       Date:  2018-04-16       Impact factor: 4.792

5.  Glycan complexity dictates microbial resource allocation in the large intestine.

Authors:  Artur Rogowski; Jonathon A Briggs; Jennifer C Mortimer; Theodora Tryfona; Nicolas Terrapon; Elisabeth C Lowe; Arnaud Baslé; Carl Morland; Alison M Day; Hongjun Zheng; Theresa E Rogers; Paul Thompson; Alastair R Hawkins; Madhav P Yadav; Bernard Henrissat; Eric C Martens; Paul Dupree; Harry J Gilbert; David N Bolam
Journal:  Nat Commun       Date:  2015-06-26       Impact factor: 14.919

6.  Maternal short-chain fructooligosaccharide supplementation influences intestinal immune system maturation in piglets.

Authors:  Cindy Le Bourgot; Stéphanie Ferret-Bernard; Laurence Le Normand; Gérard Savary; Enrique Menendez-Aparicio; Sophie Blat; Emmanuelle Appert-Bossard; Frédérique Respondek; Isabelle Le Huërou-Luron
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

7.  Postprandial glycaemic and insulinaemic responses in adults after consumption of dairy desserts and pound cakes containing short-chain fructo-oligosaccharides used to replace sugars.

Authors:  J M Lecerf; E Clerc; A Jaruga; A Wagner; F Respondek
Journal:  J Nutr Sci       Date:  2015-10-12

8.  Genome of Bifidobacteria and Carbohydrate Metabolism.

Authors:  Pauline Bondue; Véronique Delcenserie
Journal:  Korean J Food Sci Anim Resour       Date:  2015-02-28       Impact factor: 2.622

Review 9.  Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.

Authors:  Audrey Rivière; Marija Selak; David Lantin; Frédéric Leroy; Luc De Vuyst
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

10.  Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis.

Authors:  Nicholas A Scott; Anna Andrusaite; Peter Andersen; Melissa Lawson; Cristina Alcon-Giner; Charlotte Leclaire; Shabhonam Caim; Gwenaelle Le Gall; Tovah Shaw; James P R Connolly; Andrew J Roe; Hannah Wessel; Alberto Bravo-Blas; Carolyn A Thomson; Verena Kästele; Ping Wang; Daniel A Peterson; Allison Bancroft; Xuhang Li; Richard Grencis; Allan McI Mowat; Lindsay J Hall; Mark A Travis; Simon W F Milling; Elizabeth R Mann
Journal:  Sci Transl Med       Date:  2018-10-24       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.